XOMA Corporation Announces Closing of Tender Offer Apr 3, 2024 09:00AM
Kinnate Biopharma (KNTE) Sells Exarafenib to Pierre Fabre Laboratories Mar 1, 2024 08:31AM
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories Mar 1, 2024 08:30AM
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share Feb 16, 2024 08:00AM